| [Download PDF]
|Year : 2008 | Volume
| Issue : 3 | Page : 111--113
In vivo antimalarial activity of ethanolic leaf extract of Stachytarpheta cayennensis
Jude E Okokon1, Ette Ettebong1, Bassey S Antia2,
1 Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria
2 Department of Chemistry, University of Uyo, Uyo, Nigeria
Jude E Okokon
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo, Uyo
Objective: To evaluate the in vivo antiplasmodial activity of the ethanol leaf extract of Stachytarpheta cayennensis in the treatment of various ailment in Niger Delta region of Nigeria, in Plasmodium berghei infected mice.
Materials and Methods: The ethanolic leaf extract of Stachytarpheta cayennensis (90-270 mg/kg/day) was screened for blood schizonticidal activity against chloroquine sensitive Plasmodium berghei berghei in mice. The schizonticidal effect during early and established infections was investigated.
Result: Stachytarpheta cayennensis (90-270 mg/kg/day) exhibited significant (P <0.05) blood schizonticidal activity both in 4-day early infection test and in established infection with a considerable mean survival time comparable to that of the standard drug, chloroquine, 5 mg/kg/day.
Conclusion: The leaf extract possesses significant (P <0.05) antiplasmodial activity which confirms it«SQ»s use in folkloric medicine in the treatment of malaria.
|How to cite this article:|
Okokon JE, Ettebong E, Antia BS. In vivo antimalarial activity of ethanolic leaf extract of Stachytarpheta cayennensis.Indian J Pharmacol 2008;40:111-113
|How to cite this URL:|
Okokon JE, Ettebong E, Antia BS. In vivo antimalarial activity of ethanolic leaf extract of Stachytarpheta cayennensis. Indian J Pharmacol [serial online] 2008 [cited 2022 Oct 4 ];40:111-113
Available from: https://www.ijp-online.com/text.asp?2008/40/3/111/42303
Stachytarpheta cayennensis (L.C. Rich) Vahl is a weedy (and sometimes perennial) herbaceous plant from the Verbenaceae family commonly called Brazilian tea. Two common very similar species of Stachytarpheta cayennensis grow in the tropics and are use interchangeably (and share the same common names)in the herbal medicine systems of many countries, Stachytarpheta cayennensis and Stachytarpheta jamaicensis. Ethnobotanically, Stachytarpheta cayennensis is used to treat various ailments such as inflammation, pain, fever, hepatic and renal disorder, helminthiasis, constipation, hypertension, stress and diabetes. ,,, The plant is use in parts of southern Nigeria and Peru  for the treatment of malaria. Phytochemical studies of the plant revealed that it contains alkaloids,  Ipolamide, beta hydroxyipolamide and verbascoside, , steroids, triterpenes and irridoids.  Stachytarpheta cayennensis has been reported to be antiinflammtory, antinociceptive, anti ulcerogenic, ,, antidiarrheoal  as well as sedative  and hypotensive.  An insignificant in vitro antiplasmodial activity has been reported of the plant in Peru.  The aim of the present study was to evaluate the in vivo antiplasmodial potential of Stachytarpheta cayennensis considering its wide acceptability as malarial remedy in southern Nigeria.
Materials and Methods
Fresh leaves of Stachytarpheta cayennensis were procured at Uyo main market, Uyo - Akwa Ibom State of Nigeria in June, 2006 and authenticated by Dr Margaret Bassey, a taxonomist in the Department of Botany, University of Uyo, Uyo, Nigeria. A voucher specimen has been deposited in the faculty of Pharmacy hebarium, University of Uyo, Uyo. The plant material was air dried at room temperature and then powdered.
Preparation of extract
The dried and powdered leaf of Stachytarpheta cayennensis (1 kg) was exhaustively macerated in 70% ethanol for 72h.The liqiud extract obtained was concentrated in vaccum at 40 o C.The yield was 0.48%. The extract was stored in a refrigerator at 4 o C until used for experiment reported in this study. The dry ethanolic extract was dissolved in distilled water to make the stock solution from which the various doses administered were prepared for use by serial dilution.
Albino swiss mice (21-28g) of either sex were obtained from the University of Uyo animal house. They were maintained on standard animal pellets and water ad libitum. Permission and approval for animal studies were obtained from the College of Health Sciences Animal Ethics committee, University of Uyo
The chloroquine - sensitive Plasmodium berghei berghei was obtained from National Institute of Medical Research, Lagos, Nigeria and maintained in mice. The inoculum consisted of 5x10 7 P. berghei berghei parasitized erythrocytes per ml. This was prepared by determining both the percentage parasitaemia and the erythrocytes count of the donor mouse and diluting the blood with isotonic saline in proportions indicated by both determinations. Each mouse was inoculated on day 0, intraperitoneally with 0.2 mL of infected blood containing about 1 x 10 7 P. berghei beghei parasitized red blood cells.
Determination of LD 50
The LD 50 of the extract was determined using albino mice by intraperitoneal (i.p.) route using the method of Lorke. 
Evaluation of Schizontocidal Activity on early infection (4 - day test)
Schizontocidal activity of the extract was evaluated using the method described by Knight and Peters.  Each mouse was inoculated on the first day (day 0), intraperitoneally, with 0.2 ml of infected blood containing about 1x10 7 P. berghei berghei parasitized erythrocytes. The animals were divided into five groups of five mice each and orally administered, shortly after inoculation, with 90, 180 and 270 mg/kg/day doses of the Stachytarpheta cayennensis leaf extract, chloroquine 5 mg/kg/day and an equivalent volume of distilled water (negative control) for four consecutive days, (day 0 to day 3). On the fifth day (day 4), thin films were made from the tail blood of each mouse and the parasitaemia level was determined by counting the number of parasitized erythrocytes out of 200 erythrocytes in random fields of the microscope. Average percentage chemosuppression was calculated as
100 (A - B/A), where A is the average percentage parasitaemia in the negative control group and B, average percentage parasitaemia in the test group.
Evaluation of schizontocidal activity in established infection (Curative or Rane test)
Evaluation of curative potential of the extract was done using a method similar to that described by Ryley and Peter.  The mice were injected intraperitoneally with standard inoculum of 1x10 7 P. berghei berghei infected erythrocytes on the first day (day 0). Seventy-two hours later, the mice were divided into five groups of five mice each. The groups were orally administered with Stachytarpheta cayennensis leaf extract (90,180, 270 mg/kg/day), chloroquine(5 mg/kg) was given to the positive control group and an equal volume of distilled water to the negative control group. The drug/extract was given once daily for 5 days. Thin films stained with Giemsa stain were prepared from the tail blood of each mouse daily for 5 days to monitor the parasitaemia level. The mean survival time for each group was determined arithmetically by finding the average survival time (days) of the mice (post inoculation) in each group over a period of 28 days (day 0 to day 27).
Data obtained from the study were analyzed statistically using one-way ANOVA followed by a post test, Tukey-Kramer multiple comparison test and values of P Acute toxicity
The extract (500-1000 mg/kg) produced physical signs of toxicity such as writhing, gasping, palpitation, decreased respiratory rate, body and limb tone and death depending on the dose. All the mice treated with 4000 mg/kg dose of the extract and above died. The i.p LD 50 of the extract in mice was calculated to be 938.08/kg.
Ethanolic leaf extract of Stachytarpheta cayennensis produced a dose dependent chemosuppressive effect at various doses employed in this study. The chemosuppression were 64.6, 77.42 and 78.2% for 90,180 and 270 mg/kg/day doses. The chemosupression produced by the extract were significant ( P Curative test
On established infection, it was observed that there was a daily increase in parasitaemia of the control group. However, there was a daily reduction in the parasitaemia levels of the extract treated group as well as that of positive control (chloroquine).
On day 7, the average percentage parasitaemia for the groups were 7.6, 5.0, 4.6, 5.0 and 82.0% for 90, 180, 270 mg/kg/day of the extract, chloroquine and control groups respectively [Figure 1]. The mean survival time of the extract treated groups was significantly ( P Stachytarpheta cayennensis leaf is moderately toxic as shown in its LD 50 value of 938.08/kg  and also possesses a significant ( P Stachytarpheta cayennensis leaf has been reported to contain alkaloids,  Ipolamide, beta hydroxyipolamide and verbascoside, , steroids ,triterpenes and irridoids.  Antiplasmodial screening of plants have implicated alkaloids, terpenes and flavonoids in this activity. , Although the mechanism of action of this extract has not been elucidated, some plants are known to exert antiplasmodial activity either by causing red blood cell oxidation  or by inhibiting protein synthesis  depending on their phytochemical constituents. The extract could have exerted its action through either of the two mechanisms mentioned above or by some other unknown mechanism. These compounds may be acting singly or in synergy with one another to exert antiplasmodial activity observed in this study. Thus the active principle needs to be identified.
The results of this study have shown that the ethanolic leaf extract of Stachytarpheta cayennensis possesses antimalarial activity as seen in its ability to suppress Plasmodium berghei infection in the two models evaluated. This justifies the traditional usage of this plant as malarial remedy.
The authors are grateful to Mr. Nsikan Malachy for his technical assistance.
|1||Burkill HM. Stachytarpheta cayennensis: The useful plants of West Africa. Royal Botanical Gardens: Keids; 1966.|
|2||Weniger B, Robineau L. Elements para una Farmacopea Caribena, La Habana. Seminario Tramil 1988;3:243-5.|
|3||Rodriguez SM, Castro O. Evaluation farmacologica y quimica de Stachytarpheta jamaicensis (verbenaeae). Revista de Biol Trop 1996;44:353-9.|
|4||Cano JH, Volpato G. Herbal mixture in the traditional medicine of Eastern Cuba. J Ethnopharmacol 2004;90:293-316.|
|5||Kvist LP, Christensen SB, Rasmusen HB, Mejia K, Gonzalez A. Identification and evaluation of peruvian plants used to treat malaria and leishmaniasis. J Ethnopharmacol 2006;106:390-402.|
|6||Alice CB, Vargas VM, Silva GA, Siqueria NC, Schapoval EE, Gleeve J. Screening of plants used in south Brazilian folk medicine. J Ethnopharmacol 1991;35:165-71.|
|7||Kooiman P. The occurrence of iridoids glycosides in the verbenaceae. Acta Bot Neerl 1975;24:459-68.|
|8||Schapoval EE, Vargas MR, Chaves CG, Bridi R, Zuanazzi JA, Henriques AT. Antiinflammatory and antinociceptive activities of extracts and isolated compounds from Stachytarpheta cayennensis. J Ethnopharmacol 1998;60:53-9.|
|9||Futuro DO. Stachytarpheta cayennensis consideracoes quimica ecologicas. Ph.D thesis. R.J.Brazil: Universidade Federal do Rio de Janeiro; 1997.|
|10||Vela NS, Souccar C, Lima-Landman MT, Lapa AT. Inhibition of gastric acid secretion by thre acqeous extracts and purified extracts of Stachytarpheta cayennensis. Planta Med 1997;63:36-9.|
|11||Penido C, Costa KA, Futuro DO, Paiva SR, Kaplan MA, Figueiredo MR, et al. Antiinflammatory and anti- ulcerogenic properties of Stachytarpheta cayennensis (LC Rich) Vahl. J Ethnopharmacol 2006;104:225-33.|
|12||Almeida CE, Karnikowski MG, Foleto R, Baldisserotto B. Analysis of antidiarrhoeic effects of plants used in popular medicine. Revista de Saude Publica 1995;29:428-33.|
|13||Akanmu MA, Olayiwola G, Ukponwan OE, Honda K. Acute toxicity and sleep-wake EEG analysis of Stachytarpheta cayennensis (verbenaceae) in rodents. Afr J Trad Compl Alternative Med 2005;2:222-32.|
|14||Idu M, Omogbai EK, Amechina F, Ataman JE. Some cardiovascular effects of the acqeous exract of the leaves of Stachytarpheta jamaicensis. L. vahl. Int J Pharmacol 2006;2:163-5.|
|15||Lorke D. A new approach to practical acute toxicity test. Arch Toxicol 1983,54:275-86.|
|16||Knight DJ, Peters W. The antimalarial action of N-benzyloxy dihydrotriazines: The action of cycolguanil (BRL50216) against rodent malaria and studies on its mode of action. Ann Trop Med Parasitol 1980,74:393-404.|
|17||Ryley JF, Peters W. The antimalarial activity of some quinone esters. Ann Trop Med Parasitol 1970,84:209-22.|
|18||Homburger F. In vivo testing in the study of toxicity and safety evaluation. In: Marquis JK, editor. A guide to general toxicology. 2nd ed. New York: Karger; 1989.|
|19||Philipson JD, Wright CW. Antiprotozoal compounds from plants sources. Planta Med 1991;57:553-9.|
|20||Christensen SB, Kharazmi A. Antimalarial natural products. Isolation, characterization and biological properties. In: Tringali C, editor. Bioactive compounds from natural sources: Isolation, characterization and biological properties. London: Taylor and Francis; 2001. p. 379-432.|
|21||Etkin NL. Antimalarial plants used by Hausa in Northren Nigeria. Trop Doctor 1997;27:12-6.|
|22||Kirby GC, O'Neil MJ, Philipson JD, Warhurst DC. In vitro studies on the mode of action quassionoids with activity against chloroquine-resistant Plasmodium falciparum. Biochem Pharmacol 1989;38:4367-74.|